Loxo Oncology Stock Price, News & Analysis (NASDAQ:LOXO)

$75.07 0.16 (0.21 %)
(As of 11/18/2017 04:00 PM ET)
Previous Close$75.07
Today's Range$72.92 - $75.38
52-Week Range$25.25 - $95.92
Volume336,424 shs
Average Volume578,130 shs
Market Capitalization$2.24741 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.7

About Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology logoLoxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. Larotrectinib, formerly referred to as LOXO-101, is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family in development for the treatment of tumors with TRK fusions. TRK fusions have been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma, and breast cancer. LOXO-195 is a drug candidate in preclinical development. It was designed as a second-generation TRK inhibitor intended to address predicted acquired resistance mechanisms resulting from therapy with a first-generation TRK inhibitor, such as larotrectinib, or multikinase inhibitors with anti-TRK activity.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:LOXO
  • CUSIP: N/A
  • Web: www.loxooncology.com
Debt:
  • Current Ratio: 21.56%
  • Quick Ratio: 21.56%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $5.09 per share
  • Price / Book: 14.75
Profitability:
  • Trailing EPS: ($5.83)
  • Net Income: ($72,390,000.00)
  • Return on Equity: -37.71%
  • Return on Assets: -36.12%
Misc:
  • Employees: 29
  • Outstanding Shares: 29,940,000
 

Frequently Asked Questions for Loxo Oncology (NASDAQ:LOXO)

What is Loxo Oncology's stock symbol?

Loxo Oncology trades on the NASDAQ under the ticker symbol "LOXO."

How were Loxo Oncology's earnings last quarter?

Loxo Oncology, Inc. (NASDAQ:LOXO) announced its quarterly earnings data on Wednesday, August, 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.63) by $0.14. View Loxo Oncology's Earnings History.

Where is Loxo Oncology's stock going? Where will Loxo Oncology's stock price be in 2017?

8 brokers have issued 1 year price objectives for Loxo Oncology's stock. Their predictions range from $50.00 to $108.00. On average, they anticipate Loxo Oncology's share price to reach $92.00 in the next twelve months. View Analyst Ratings for Loxo Oncology.

What are Wall Street analysts saying about Loxo Oncology stock?

Here are some recent quotes from research analysts about Loxo Oncology stock:

  • 1. According to Zacks Investment Research, "Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. " (8/12/2017)
  • 2. BTIG Research analysts commented, "Today LOXO announced the acquisition of REDX08608 (LOXO-305) from Redx Pharma (REDX, Not Rated), a reversible BTK inhibitor that is effective against both wild-type and mutant C481S BTK. We view the acquisition of REDX08608 positively, as the ~$40m upfront acquisition cost is relatively devoid of downstream payments (milestones etc.), and despite the BTK space being competitive with next generation programs to ibrutinib, we think there will be ample room for multiple BTK inhibitors and we also favor the selectivity of LOXO-305. Management has guided for the submission of an IND during 2018. We reiterate our Buy rating and $75 PT." (8/3/2017)

Who are some of Loxo Oncology's key competitors?

Who are Loxo Oncology's key executives?

Loxo Oncology's management team includes the folowing people:

  • Joshua H. Bilenker M.D., President, Chief Executive Officer, Director (Age 45)
  • Jennifer Burstein CPA, Vice President - Finance (Age 45)
  • Jacob S. Van Naarden, Chief Business Officer (Age 32)
  • Keith T. Flaherty M.D., Director (Age 46)
  • Lori A. Kunkel M.D., Director (Age 59)
  • David Bonita M.D., Independent Director (Age 41)
  • Steven A. Elms, Independent Director (Age 53)
  • Alan Fuhrman, Independent Director (Age 60)

Who owns Loxo Oncology stock?

Loxo Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (1.46%), Sectoral Asset Management Inc (0.82%), Pictet Asset Management Ltd. (0.81%), Ameriprise Financial Inc. (0.43%), Bank of New York Mellon Corp (0.41%) and Schwab Charles Investment Management Inc. (0.35%). Company insiders that own Loxo Oncology stock include Aisling Capital Iii Lp, Avi Z Naider, David P Bonita, Jennifer Burstein, Joshua H Bilenker, Keith T Flaherty, Lori Anne Kunkel and Naarden Jacob Van. View Institutional Ownership Trends for Loxo Oncology.

Who sold Loxo Oncology stock? Who is selling Loxo Oncology stock?

Loxo Oncology's stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Crawford Lake Capital Management LLC, JPMorgan Chase & Co., Prudential Financial Inc., EAM Investors LLC, Alyeska Investment Group L.P., Russell Investments Group Ltd. and Nationwide Fund Advisors. Company insiders that have sold Loxo Oncology company stock in the last year include Avi Z Naider, Jennifer Burstein, Joshua H Bilenker, Keith T Flaherty, Lori Anne Kunkel and Naarden Jacob Van. View Insider Buying and Selling for Loxo Oncology.

Who bought Loxo Oncology stock? Who is buying Loxo Oncology stock?

Loxo Oncology's stock was purchased by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Candriam Luxembourg S.C.A., Jane Street Group LLC, Schwab Charles Investment Management Inc., Sectoral Asset Management Inc, Cornerstone Capital Management Holdings LLC., Legal & General Group Plc and Alps Advisors Inc.. View Insider Buying and Selling for Loxo Oncology.

How do I buy Loxo Oncology stock?

Shares of Loxo Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Loxo Oncology's stock price today?

One share of Loxo Oncology stock can currently be purchased for approximately $75.07.

How big of a company is Loxo Oncology?

Loxo Oncology has a market capitalization of $2.24741 billion. The biopharmaceutical company earns ($72,390,000.00) in net income (profit) each year or ($5.83) on an earnings per share basis. Loxo Oncology employs 29 workers across the globe.

How can I contact Loxo Oncology?

Loxo Oncology's mailing address is 281 TRESSER BOULEVARD 9TH FLOOR, STAMFORD CT, 06901. The biopharmaceutical company can be reached via phone at 203-653-3880 or via email at [email protected]


MarketBeat Community Rating for Loxo Oncology (NASDAQ LOXO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  294
MarketBeat's community ratings are surveys of what our community members think about Loxo Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Loxo Oncology (NASDAQ:LOXO)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 7 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.13)
Consensus Price Target: $92.00 (22.55% upside)

Consensus Price Target History for Loxo Oncology (NASDAQ:LOXO)

Price Target History for Loxo Oncology (NASDAQ:LOXO)

Analysts' Ratings History for Loxo Oncology (NASDAQ:LOXO)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017Citigroup Inc.Lower Price TargetBuy$112.00 -> $108.00N/AView Rating Details
11/14/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$77.18 -> $95.00N/AView Rating Details
11/14/2017Ifs SecuritiesUpgradeOutperform -> Strong-BuyN/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$95.00 -> $103.00N/AView Rating Details
9/29/2017BTIG ResearchReiterated RatingBuy$75.00 -> $102.00LowView Rating Details
9/28/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
8/10/2017Stifel NicolausReiterated RatingBuy$71.00 -> $94.00HighView Rating Details
2/8/2017Jefferies Group LLCInitiated CoverageBuy$50.00N/AView Rating Details
4/19/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$30.00N/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Loxo Oncology (NASDAQ:LOXO)

Earnings by Quarter for Loxo Oncology (NASDAQ:LOXO)

Earnings History by Quarter for Loxo Oncology (NASDAQ LOXO)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.99)($1.14)ViewN/AView Earnings Details
5/9/2017Q1 2017($0.76)($0.96)ViewN/AView Earnings Details
3/7/2017Q4 2016($0.85)($1.28)ViewN/AView Earnings Details
11/2/2016Q316($0.74)($0.82)ViewN/AView Earnings Details
8/3/2016Q2($0.63)($0.77)ViewN/AView Earnings Details
5/4/2016Q1($0.69)($0.59)ViewN/AView Earnings Details
3/15/2016Q4($0.53)($0.73)ViewN/AView Earnings Details
11/10/2015Q3($0.53)($0.53)ViewN/AView Earnings Details
8/5/2015Q215($0.45)($0.49)ViewListenView Earnings Details
5/14/2015Q1($0.50)($0.38)ViewN/AView Earnings Details
11/14/2014Q314($0.37)($0.68)ViewN/AView Earnings Details
9/12/2014Q2 2014($12.27)($14.46)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Loxo Oncology (NASDAQ:LOXO)
2017 EPS Consensus Estimate: ($3.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.75)($0.75)($0.75)
Q2 20171($0.83)($0.83)($0.83)
Q3 20171($0.92)($0.92)($0.92)
Q4 20171($1.18)($1.18)($1.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Loxo Oncology (NASDAQ:LOXO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Loxo Oncology (NASDAQ LOXO)

Insider Ownership Percentage: 27.80%
Insider Trades by Quarter for Loxo Oncology (NASDAQ:LOXO)
Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Insider Trades by Quarter for Loxo Oncology (NASDAQ LOXO)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/2/2017Lori Anne KunkelDirectorSell5,000$84.91$424,550.00View SEC Filing  
10/31/2017Joshua H BilenkerCEOSell7,500$86.49$648,675.00View SEC Filing  
10/31/2017Naarden Jacob VanInsiderSell1,541$86.52$133,327.32View SEC Filing  
10/30/2017Jennifer BursteinVPSell1,700$87.19$148,223.00View SEC Filing  
10/16/2017Avi Z NaiderDirectorSell5,000$90.00$450,000.00View SEC Filing  
9/19/2017Joshua H BilenkerCEOSell15,000$89.02$1,335,300.00View SEC Filing  
9/19/2017Naarden Jacob VanInsiderSell3,082$89.00$274,298.00View SEC Filing  
9/18/2017Avi Z NaiderDirectorSell5,000$90.00$450,000.00View SEC Filing  
9/18/2017Jennifer BursteinVPSell1,700$89.10$151,470.00View SEC Filing  
9/18/2017Joshua H BilenkerCEOSell7,500$89.25$669,375.00View SEC Filing  
9/18/2017Naarden Jacob VanInsiderSell1,541$89.20$137,457.20View SEC Filing  
9/13/2017Avi Z NaiderDirectorSell5,000$90.00$450,000.00View SEC Filing  
8/22/2017Lori Anne KunkelDirectorSell10,000$75.17$751,700.00View SEC Filing  
8/21/2017Keith T FlahertyDirectorSell7,250$72.26$523,885.00View SEC Filing  
8/15/2017Joshua H BilenkerCEOSell15,000$73.56$1,103,400.00View SEC Filing  
8/15/2017Naarden Jacob VanInsiderSell3,082$73.57$226,742.74View SEC Filing  
8/14/2017Jennifer BursteinVPSell1,700$73.73$125,341.00View SEC Filing  
8/14/2017Joshua H BilenkerCEOSell7,500$73.73$552,975.00View SEC Filing  
8/14/2017Naarden Jacob VanInsiderSell1,541$73.73$113,617.93View SEC Filing  
5/22/2017Keith T FlahertyDirectorSell7,250$45.09$326,902.50View SEC Filing  
1/10/2017Aisling Capital Iii LpMajor ShareholderBuy160,000$31.00$4,960,000.00View SEC Filing  
12/19/2016Keith T FlahertyDirectorSell7,250$30.23$219,167.50View SEC Filing  
9/7/2016Keith T FlahertyDirectorSell14,500$30.00$435,000.00View SEC Filing  
8/11/2016Keith T FlahertyDirectorSell15,000$26.00$390,000.00View SEC Filing  
8/10/2016David P BonitaDirectorSell447,857$26.96$12,074,224.72View SEC Filing  
5/17/2016Aisling Capital Iii LpMajor ShareholderBuy232,558$21.50$4,999,997.00View SEC Filing  
11/17/2015Avi Z NaiderDirectorBuy3,773$26.50$99,984.50View SEC Filing  
11/13/2015Aisling Capital Iii LpMajor ShareholderBuy78,669$27.65$2,175,197.85View SEC Filing  
8/6/2014James E FlynnInsiderBuy1,089,656$13.01$14,176,424.56View SEC Filing  
8/6/2014Orbimed Advisors LlcMajor ShareholderBuy275,385$13.00$3,580,005.00View SEC Filing  
8/6/2014Steve ElmsDirectorBuy413,077$13.00$5,370,001.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Loxo Oncology (NASDAQ LOXO)

Source:
DateHeadline
Is Loxo Oncologys Deal With Bayer Bad News? - NasdaqIs Loxo Oncology's Deal With Bayer Bad News? - Nasdaq
www.nasdaq.com - November 19 at 7:18 PM
Investors Purchase Large Volume of Call Options on Loxo Oncology (LOXO)Investors Purchase Large Volume of Call Options on Loxo Oncology (LOXO)
www.americanbankingnews.com - November 18 at 2:02 AM
Traders Buy Large Volume of Put Options on Loxo Oncology (LOXO)Traders Buy Large Volume of Put Options on Loxo Oncology (LOXO)
www.americanbankingnews.com - November 17 at 2:54 AM
Citigroup Inc. Lowers Loxo Oncology, Inc. (LOXO) Price Target to $108.00Citigroup Inc. Lowers Loxo Oncology, Inc. (LOXO) Price Target to $108.00
www.americanbankingnews.com - November 16 at 6:50 PM
Loxo Oncology Enters Oversold Territory (LOXO)Loxo Oncology Enters Oversold Territory (LOXO)
www.nasdaq.com - November 15 at 5:35 AM
Loxo Oncology (LOXO) Announces Pact with Bayer for Larotrectinib and LOXO-195Loxo Oncology (LOXO) Announces Pact with Bayer for Larotrectinib and LOXO-195
www.streetinsider.com - November 15 at 5:35 AM
BRIEF-Loxo Oncology announces development and commercialization partnership with Bayer for cancer drugsBRIEF-Loxo Oncology announces development and commercialization partnership with Bayer for cancer drugs
www.reuters.com - November 15 at 5:35 AM
Loxo Loses Out Despite Signing Big Cancer DealLoxo Loses Out Despite Signing Big Cancer Deal
247wallst.com - November 15 at 5:35 AM
Loxo Sells Bayer Rights To Rare Cancer Drug For More Than $1 BillionLoxo Sells Bayer Rights To Rare Cancer Drug For More Than $1 Billion
finance.yahoo.com - November 15 at 5:35 AM
Loxo, Bayer to co-develop cancer drugs in up to $1.55 bln dealLoxo, Bayer to co-develop cancer drugs in up to $1.55 bln deal
finance.yahoo.com - November 15 at 5:35 AM
What Is Loxo Oncology Inc’s (LOXO) Share Price Doing?What Is Loxo Oncology Inc’s (LOXO) Share Price Doing?
finance.yahoo.com - November 15 at 5:35 AM
Loxos Good Deed Goes PunishedLoxo's Good Deed Goes Punished
finance.yahoo.com - November 15 at 5:35 AM
Loxo Oncology, Inc. (LOXO) Rating Increased to Strong-Buy at Ifs SecuritiesLoxo Oncology, Inc. (LOXO) Rating Increased to Strong-Buy at Ifs Securities
www.americanbankingnews.com - November 14 at 6:36 PM
Loxo Oncology, Inc. (LOXO) Upgraded to Outperform at JMP SecuritiesLoxo Oncology, Inc. (LOXO) Upgraded to Outperform at JMP Securities
www.americanbankingnews.com - November 14 at 4:00 PM
Array BioPharma Reports Initial Results From Novel Immunotherapy Combination At The Society For Immunotherapy Of Cancer (SITC) 32nd Annual MeetingArray BioPharma Reports Initial Results From Novel Immunotherapy Combination At The Society For Immunotherapy Of Cancer (SITC) 32nd Annual Meeting
www.bizjournals.com - November 13 at 5:12 PM
-$1.29 EPS Expected for Loxo Oncology, Inc. (LOXO) This Quarter-$1.29 EPS Expected for Loxo Oncology, Inc. (LOXO) This Quarter
www.americanbankingnews.com - November 11 at 3:26 PM
Loxo Oncology, Inc. (LOXO) Director Lori Anne Kunkel Sells 5,000 SharesLoxo Oncology, Inc. (LOXO) Director Lori Anne Kunkel Sells 5,000 Shares
www.americanbankingnews.com - November 6 at 6:58 PM
Loxo Oncology Announces Third Quarter 2017 Financial ResultsLoxo Oncology Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 4 at 1:25 AM
Loxo Oncology Announces Third Quarter 2017 Financial Results - GlobeNewswire (press release)Loxo Oncology Announces Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 3 at 3:23 PM
Loxo Oncology Inc to Host Earnings CallLoxo Oncology Inc to Host Earnings Call
finance.yahoo.com - November 3 at 3:23 PM
Loxo Oncology Announces Third Quarter 2017 Financial ResultsLoxo Oncology Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 3 at 3:23 PM
Loxo reports 3Q lossLoxo reports 3Q loss
finance.yahoo.com - November 3 at 3:23 PM
Edited Transcript of LOXO earnings conference call or presentation 2-Nov-17 12:00pm GMTEdited Transcript of LOXO earnings conference call or presentation 2-Nov-17 12:00pm GMT
finance.yahoo.com - November 3 at 3:23 PM
Schrödinger Appoints Dov Goldstein, M.D., as Chief Financial OfficerSchrödinger Appoints Dov Goldstein, M.D., as Chief Financial Officer
www.bizjournals.com - November 2 at 5:56 AM
Insider Selling: Loxo Oncology, Inc. (LOXO) VP Sells 1,700 Shares of StockInsider Selling: Loxo Oncology, Inc. (LOXO) VP Sells 1,700 Shares of Stock
www.americanbankingnews.com - November 1 at 5:44 PM
Loxo Oncology, Inc. (LOXO) Insider Naarden Jacob Van Sells 1,541 SharesLoxo Oncology, Inc. (LOXO) Insider Naarden Jacob Van Sells 1,541 Shares
www.americanbankingnews.com - November 1 at 5:44 PM
Joshua H. Bilenker Sells 7,500 Shares of Loxo Oncology, Inc. (LOXO) StockJoshua H. Bilenker Sells 7,500 Shares of Loxo Oncology, Inc. (LOXO) Stock
www.americanbankingnews.com - November 1 at 5:26 PM
Critical Contrast: Loxo Oncology (LOXO) vs. Its CompetitorsCritical Contrast: Loxo Oncology (LOXO) vs. Its Competitors
www.americanbankingnews.com - October 30 at 12:58 AM
Loxo Oncology to Announce Third Quarter 2017 Financial Results and Host Conference Call - GlobeNewswire (press release)Loxo Oncology to Announce Third Quarter 2017 Financial Results and Host Conference Call - GlobeNewswire (press release)
globenewswire.com - October 27 at 5:15 AM
Loxo Oncology to Announce Third Quarter 2017 Financial Results and Host Conference CallLoxo Oncology to Announce Third Quarter 2017 Financial Results and Host Conference Call
finance.yahoo.com - October 27 at 5:15 AM
Loxo Oncology Inc (LOXO) Given Consensus Rating of "Buy" by BrokeragesLoxo Oncology Inc (LOXO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 26 at 5:48 PM
Stocks of Drug Upstarts Churn Amid Wider Markets Steady Climb - BloombergStocks of Drug Upstarts Churn Amid Wider Market's Steady Climb - Bloomberg
www.bloomberg.com - October 23 at 8:14 PM
Loxo Oncology, Inc. (LOXO) Set to Announce Earnings on MondayLoxo Oncology, Inc. (LOXO) Set to Announce Earnings on Monday
www.americanbankingnews.com - October 23 at 12:52 PM
 Analysts Anticipate Loxo Oncology, Inc. (LOXO) Will Announce Earnings of -$1.05 Per Share Analysts Anticipate Loxo Oncology, Inc. (LOXO) Will Announce Earnings of -$1.05 Per Share
www.americanbankingnews.com - October 22 at 4:24 PM
Comparing Loxo Oncology (LOXO) and Its CompetitorsComparing Loxo Oncology (LOXO) and Its Competitors
www.americanbankingnews.com - October 21 at 2:24 AM
Loxo Oncology, Inc. (LOXO) Price Target Raised to $112.00 at Citigroup Inc.Loxo Oncology, Inc. (LOXO) Price Target Raised to $112.00 at Citigroup Inc.
www.americanbankingnews.com - October 20 at 9:10 AM
Commit To Purchase Loxo Oncology At $70, Earn 10.2% Annualized Using OptionsCommit To Purchase Loxo Oncology At $70, Earn 10.2% Annualized Using Options
www.nasdaq.com - October 20 at 5:27 AM
Loxo Oncology, Inc. (LOXO) Director Sells $450,000.00 in StockLoxo Oncology, Inc. (LOXO) Director Sells $450,000.00 in Stock
www.americanbankingnews.com - October 18 at 7:46 PM
Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of ... - GlobeNewswire (press release)Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of ... - GlobeNewswire (press release)
globenewswire.com - October 18 at 6:38 AM
Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib DatasetLoxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset
finance.yahoo.com - October 18 at 6:37 AM
Buying And Selling Stocks Right Are Keys To This Top Mutual Fund's SuccessBuying And Selling Stocks Right Are Keys To This Top Mutual Fund's Success
finance.yahoo.com - October 16 at 3:21 PM
Loxo Oncology Fights Cancer With 'Tumor Agnostic' ApproachLoxo Oncology Fights Cancer With 'Tumor Agnostic' Approach
finance.yahoo.com - October 16 at 3:21 PM
6 Top Biotech Companies In Innovation Earn Recognition In New Awards6 Top Biotech Companies In Innovation Earn Recognition In New Awards
finance.yahoo.com - October 16 at 3:21 PM
Morgan Stanley Reiterates "Overweight" Rating for Loxo Oncology, Inc. (LOXO)Morgan Stanley Reiterates "Overweight" Rating for Loxo Oncology, Inc. (LOXO)
www.americanbankingnews.com - October 7 at 12:00 PM
Todays Research Reports on Stocks to Watch: Zynerba Pharmaceuticals and Loxo OncologyToday's Research Reports on Stocks to Watch: Zynerba Pharmaceuticals and Loxo Oncology
finance.yahoo.com - October 2 at 12:15 PM
How Does Investing In Loxo Oncology Inc (LOXO) Impact Your Portfolio?How Does Investing In Loxo Oncology Inc (LOXO) Impact Your Portfolio?
finance.yahoo.com - October 2 at 12:15 PM
Loxo Oncology, Inc. (LOXO) Given Consensus Recommendation of "Buy" by BrokeragesLoxo Oncology, Inc. (LOXO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 1 at 2:38 PM
Loxo Oncology, Inc. (LOXO) Given "Buy" Rating at BTIG ResearchLoxo Oncology, Inc. (LOXO) Given "Buy" Rating at BTIG Research
www.americanbankingnews.com - September 29 at 6:00 PM
Loxo Oncology Inc (LOXO) Rating Reiterated by Cowen and CompanyLoxo Oncology Inc (LOXO) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - September 28 at 10:52 PM
Health Care Sector Update for 09/28/2017: LOXO,ZYNE,DXCM - NasdaqHealth Care Sector Update for 09/28/2017: LOXO,ZYNE,DXCM - Nasdaq
www.nasdaq.com - September 28 at 6:37 PM

Social Media

Financials

Chart

Loxo Oncology (NASDAQ LOXO) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.